deltatrials
Terminated PHASE3 INTERVENTIONAL 2-arm NCT05568888

Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )

A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE1116 (4-Factor Prothrombin Complex Concentrate [Kcentra® / Beriplex®]) to Improve Survival in Patients With Traumatic Injury and Acute Major Bleeding

Sponsor: CSL Behring

Interventions BE1116 Placebo
Updated 19 times since 2022 Last updated: Nov 24, 2025 Started: Mar 28, 2023 Primary completion: Oct 29, 2024 Completion: Oct 29, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study was terminated early because mortality was lower than expected and a significant increase in sample size would have been required to meet statistical goals of the study. No safety reasons were involved in the decision to terminate the study.

This PHASE3 trial investigates Traumatic Injury and is currently terminated or withdrawn. CSL Behring leads this study, which shows 19 recorded versions since 2023 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Nov 2022 – ~Apr 2023 · 5 months · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Feb 2024 · 2 months · monthly snapshot~Feb 2024 – ~Apr 2024 · 2 months · monthly snapshot~Apr 2024 – ~Jun 2024 · 2 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Sep 2025 · 9 months · monthly snapshot~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshot~Dec 2025 – ~Jan 2026 · 31 days · monthly snapshot~Jan 2026 – present · 6 months · monthly snapshot

Change History

19 versions recorded
  1. Jan 2026 — Present [monthly]

    Terminated PHASE3

  2. Dec 2025 — Jan 2026 [monthly]

    Terminated PHASE3

  3. Sep 2025 — Dec 2025 [monthly]

    Terminated PHASE3

  4. Dec 2024 — Sep 2025 [monthly]

    Terminated PHASE3

    Status: RecruitingTerminated

  5. Sep 2024 — Dec 2024 [monthly]

    Recruiting PHASE3

Show 14 earlier versions
  1. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE3

  2. Jun 2024 — Jul 2024 [monthly]

    Recruiting PHASE3

  3. Apr 2024 — Jun 2024 [monthly]

    Recruiting PHASE3

  4. Feb 2024 — Apr 2024 [monthly]

    Recruiting PHASE3

  5. Dec 2023 — Feb 2024 [monthly]

    Recruiting PHASE3

  6. Nov 2023 — Dec 2023 [monthly]

    Recruiting PHASE3

  7. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE3

  8. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE3

  9. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE3

  10. Jul 2023 — Aug 2023 [monthly]

    Recruiting PHASE3

  11. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE3

  12. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE3

    Status: Active Not RecruitingRecruiting

  13. Apr 2023 — May 2023 [monthly]

    Active Not Recruiting PHASE3

    Status: Not Yet RecruitingActive Not Recruiting

  14. Nov 2022 — Apr 2023 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • CSL Behring
Data source: CSL Behring

For direct contact, visit the study record on ClinicalTrials.gov .